Lepu Biopharma Co., Ltd.
HKSE 2157.HK
Lepu Biopharma Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -162.28
-
Lepu Biopharma Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -154.82 on January 13, 2025, which is 4.60% above the current Price to Earnings Ratio (P/E).
-
Lepu Biopharma Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -448.05 on May 03, 2024, which is -176.09% below the current Price to Earnings Ratio (P/E).
-
Lepu Biopharma Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -240.65.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Ziye Sui M.D., Ph.D. |
| IPO Date | Feb. 23, 2022 |
| Location | China |
| Headquarters | Building 41 |
| Employees | 491 |
| Sector | Health Care |
| Industries | |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
Past 5 years
USD 3.69
USD 1.06
StockViz Staff
January 15, 2025
Any question? Send us an email